Evidence map›Paper›PMID 31582539›Full record

ArticleHaematologica2020

An intronic deletion in megakaryoblastic leukemia 1 is associated with hyperproliferation of B cells in triplets with Hodgkin lymphoma.

Julien Record, Anton Sendel, Joanna S Kritikou, Nikolai V Kuznetsov, Hanna Brauner, Minghui He, Noemi Nagy, Mariana M S Oliveira, Elena Griseti, Christoph B Haase and 11 more

Open access · goldAbstract read
In one paragraph

Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 3 countries.

Julien RecordDepartment of Microbiology, Tumor and Cell Biology, Biomedicum, Karolinska Institutet, Stockholm, Sweden.
Anton SendelDepartment of Microbiology, Tumor and Cell Biology, Biomedicum, Karolinska Institutet, Stockholm, Sweden.
Joanna S KritikouDepartment of Microbiology, Tumor and Cell Biology, Biomedicum, Karolinska Institutet, Stockholm, Sweden.
Nikolai V KuznetsovDepartment of Microbiology, Tumor and Cell Biology, Biomedicum, Karolinska Institutet, Stockholm, Sweden.
Hanna BraunerDepartment of Microbiology, Tumor and Cell Biology, Biomedicum, Karolinska Institutet, Stockholm, Sweden.
Minghui HeDepartment of Microbiology, Tumor and Cell Biology, Biomedicum, Karolinska Institutet, Stockholm, Sweden.
Noemi NagyDepartment of Microbiology, Tumor and Cell Biology, Biomedicum, Karolinska Institutet, Stockholm, Sweden.
Mariana M S OliveiraDepartment of Microbiology, Tumor and Cell Biology, Biomedicum, Karolinska Institutet, Stockholm, Sweden.
Elena GrisetiDepartment of Microbiology, Tumor and Cell Biology, Biomedicum, Karolinska Institutet, Stockholm, Sweden.
Christoph B HaaseDepartment of Microbiology, Tumor and Cell Biology, Biomedicum, Karolinska Institutet, Stockholm, Sweden.
Jenny DahlströmDepartment of Medicine Solna, Karolinska University Hospital, Stockholm, Sweden.
Sanjaykumar BoddulDepartment of Medicine Solna, Karolinska University Hospital, Stockholm, Sweden.
Fredrik WermelingDepartment of Medicine Solna, Karolinska University Hospital, Stockholm, Sweden.
Adrian J ThrasherInstitute of Child Health, University College London, London, UK.
Chaohong LiuDepartment of Pathogen Biology, School of Basic Medicine, Huazhong University of Science and Technology, Wuhan, China.
John AnderssonDepartment of Microbiology, Tumor and Cell Biology, Biomedicum, Karolinska Institutet, Stockholm, Sweden.
Hans-Erik ClaessonDepartment of Medicine Solna, Karolinska University Hospital, Stockholm, Sweden.
Ola WinqvistDepartment of Medicine Solna, Karolinska University Hospital, Stockholm, Sweden.
Siobhan O BurnsInstitute of Immunity and Transplantation, University College London, London, UK.
Magnus BjörkholmDepartment of Medicine Solna, Karolinska University Hospital, Stockholm, Sweden.
Lisa S WesterbergDepartment of Microbiology, Tumor and Cell Biology, Biomedicum, Karolinska Institutet, Stockholm, Sweden lisa.westerberg@ki.se.
Karolinska Institutet · SEKarolinska University Hospital · SEHuazhong University of Science and Technology · CNRoyal Free London NHS Foundation Trust · GBUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Megakaryoblastic leukemia 1 (MKL1) is a coactivator of serum response factor and together they regulate transcription of actin cytoskeleton genes. MKL1 is associated with hematologic malignancies and immunodeficiency, but its role in B cells is unexplored. Here we examined B cells from monozygotic triplets with an intronic deletion in

Indexed as

Epstein-Barr Virus InfectionsHodgkin DiseaseB-LymphocytesCells, CulturedHerpesvirus 4, HumanHumans

Identifiers

PMID31582539
PMCPMC7193474
OpenAlexW2978025197

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.